Novel Coronavirus (SARS-CoV-2/COVID-19)
The National Institute of Allergy and Infectious Diseases has launched a clinical trial to evaluate a potential COVID-19 treatment regimen for hospitalized patients that combines remdesivir with interferon beta-1a, a medication approved to treat multiple sclerosis that laboratory studies suggest…
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, our clinical partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership groups…
Join AHA’s Board Chair Dr. Mindy Estes for Leadership Rounds as she discusses key issues with Dr. Harsh K. Trivedi, President and CEO, Sheppard Pratt. Watch the live stream at 3:30 p.m. to 3:45 p.m. ET/2:30 p.m. to 2:45 p.m. CT/12:30 a.m. to 12:45 a.m. PT, and come back to listen to the podcast and…
More than one in four individuals in a recent national survey reported they would wait four months or longer to seek previously skipped medical care due to fear of COVID-19.
Health care facilities or providers facing inadequate supplies of certain drugs needed to treat patients with COVID-19 should not use the products more than four hours beyond the labeled “in-use time” for refrigerated storage or two hours beyond the labeled “in-use time” for room temperature…
The departments of Health and Human Services and Defense will pay Janssen Pharmaceutical Companies of Johnson & Johnson $1 billion to manufacture 100 million doses of its COVID-19 vaccine candidate for use in clinical trials, or to vaccinate Americans if authorized by the Food and Drug…
Patient safety has always been the number one priority for hospitals and health care providers, and COVID-19 has not changed that one bit. In fact, the safety protocols put into place for patients, families, care providers and staff since the pandemic’s onset are the most stringent they’ve ever…
A series of free videos from Med Tac offers guidance on how essential workers and the public can stay safe during the COVID-19 public health emergency.
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia convened a virtual summit to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.
The National Institutes of Health announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.